Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00183820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Jul 1, 2026 Secondary endpoints: 1 to 2v18 Show 1 more changeShow less
    • Secondary endpoints: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Active, Not Recruiting to Completed Study completion date changed from estimate of Jun 2016 to Aug 2016v17 Show 1 more changeShow less
    • Study completion date changed from estimate of Jun 2016 to Aug 2016
  3. Primary completion date: Dec 2014 to Dec 2015 Completion date: Jun 2015 to Jun 2016v16 Show 1 more changeShow less
    • Completion date: Jun 2015 to Jun 2016
  4. Re-verified, no change to tracked fieldsv15
  5. Primary completion date: Dec 2013 to Dec 2014 Completion date: Jun 2014 to Jun 2015v14 Show 1 more changeShow less
    • Completion date: Jun 2014 to Jun 2015
Show 12 earlier versionsHide 12 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 20 to confirmed 30 · Site details revisedv13 Show 2 more changesShow less
    • Enrollment target: estimated 20 to confirmed 30
    • Site details revised
  2. Primary completion date: Dec 2012 to Dec 2013 Completion date: Jun 2013 to Jun 2014v12 Show 1 more changeShow less
    • Completion date: Jun 2013 to Jun 2014
  3. Primary completion date: Dec 2011 to Dec 2012 Completion date: Jun 2012 to Jun 2013v11 Show 1 more changeShow less
    • Completion date: Jun 2012 to Jun 2013
  4. Primary completion date: Jan 2010 to Dec 2011 Completion date: Jan 2010 to Jun 2012v10 Show 1 more changeShow less
    • Completion date: Jan 2010 to Jun 2012
  5. 2 versions Re-verified since Jul 24, 2009, no change to tracked fieldsv8-v9
  6. Primary and study completion dates: Jan 2009 to Jan 2010v7
  7. Interventions: paclitaxel, gemcitabine and oxaliplatin (Drug) to paclitaxel, gemcitabine, and oxaliplatin (Drug) Eligibility criteria expanded, about 5 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  8. Re-verified, no change to tracked fieldsv5
  9. Enrollment target: 20 Primary completion date: Jan 2009 · Completion date: Apr 2008 to Jan 2009 · Interventions: Gemcitabine, oxaliplatin, paclitaxel (Drug) to paclitaxel, gemcitabine and oxaliplatin (Drug) · 3 morev4 Show 6 more changesShow less
    • Primary completion date: Jan 2009
    • Completion date: Apr 2008 to Jan 2009
    • Interventions: Gemcitabine, oxaliplatin, paclitaxel (Drug) to paclitaxel, gemcitabine and oxaliplatin (Drug)
    • Eligibility criteria revised
    • Site contact updated
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  10. Completion date: Apr 2006 to Apr 2008v3
  11. Completion date: Apr 2006v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Trial Details
NCT Number NCT00183820
Lead Sponsor University of Southern California
Collaborators: Sanofi
Conditions Testicular Cancer, Germ Cell Neoplasm
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov